Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06815991 · ClinicalTrials.gov registry record · Phase 1
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
A Phase 1 study of Healthy Adults, sponsored by Metro International Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06815991: Recruiting Phase 1 study of Healthy Adults, sponsored by Metro International Biotech.
NCT06815991 is a Phase 1 study of Healthy Adults that is actively recruiting participants, run by Metro International Biotech. The registered enrollment target is 32 participants, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06815991, a Phase 1 study of Healthy Adults, is actively recruiting participants, sponsored by Metro International Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, open label (i.e. participants and study staff will not be masked to the intervention) single ascending dose study to evaluate the safety, tolerability, pharmaokinetics and pharmacodynamics of MIB-725 in community dwelling, healthy adults. Up to 4 successive groups (cohorts) of 8 subjects each will be enrolled in this trial. This study will determine the safety and tolerability of orally administered single ascending (increasing) doses (100, 200, 400, and 800 mg) of MIB-725 in healthy adults. The safety will be assessed by evaluating physical examination that includes an external eye examination, vital signs, adverse events, and changes in blood counts, EKG, urinalysis, coagulation measures, and blood chemistries, including but not limited to blood glucose, electrolytes, creatinine, liver function tests, uric acid, and creatine kinase.
Primary Outcome
Any treatment-emergent adverse events, including any ocular adverse events
Conditions Studied
Interventions
- DRUG MIB-725
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT06815991 shows while recruiting
NCT06815991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 1 intervention - of which MIB-725 is the first listed.
NCT06815991 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06815991 about?
NCT06815991 is a clinical study titled "Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults". This is a single center, open label (i.e. participants and study staff will not be masked to the intervention) single ascending dose study to evaluate the safety, tolerability, pharmaokinetics and pharmacodynamics of MIB-725 in community dwelling, healthy adults. Up to 4 successive groups (cohorts) ...
What is the current status of trial NCT06815991?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-02-11. Estimated completion is 2027-03.
What conditions does trial NCT06815991 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT06815991?
The interventions under investigation include: MIB-725 (DRUG).
Who is sponsoring clinical trial NCT06815991?
This trial is sponsored by Metro International Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06815991 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06815991's enrollment target sits among peer trials
32 19th of 33 higher than 14 of 33 other Healthy Adults trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
RECRUITING · Phase 1
-
Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
RECRUITING · Phase 1
-
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
RECRUITING · Phase 1
-
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI